- Home
- ANTA vs NRXS Comparison
ANTA vs NRXS Comparison
Compare ANTA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ANTA | NRXS |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 78.9M |
| IPO Year | 2024 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ANTA | NRXS |
|---|---|---|
| Price | $3.58 | $6.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.17 | $13.00 |
| AVG Volume (30 Days) | 4.5K | ★ 93.0K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | $21.95 | $172.91 |
| Revenue Next Year | $30.46 | $115.71 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $3.00 | $2.21 |
| 52 Week High | $13.82 | $9.33 |
Technical Indicators
Market Signals| Indicator | ANTA | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 41.86 |
| Support Level | $3.00 | $5.77 |
| Resistance Level | $4.17 | $7.62 |
| Average True Range (ATR) | 0.31 | 0.49 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 49.57 | 47.37 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).